How does Viridian’s Lumvoa compare to Amgen’s Tepezza for thyroid eye disease?

Viridian’s Lumvoa has gained FDA approval as the second therapy for thyroid eye disease, competing directly with Amgen’s Tepezza. Lumvoa offers shorter infusions—about 30–40 minutes versus 60–90—and fewer treatments over 12 weeks. Its approval spans both active and chronic TED, potentially challenging Tepezza’s market dominance.